Institut régional du Cancer de Montpellier - ICM Val d'Aurelle

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Sacituzumab Govitecan in Primary HER2-negative Breast Cancer	Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder, triple-negative breast carcinoma	Active, not recruiting	Phase 3	2026-04-22		NCT04595565
Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancer	Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, Nutritional and Metabolic Diseases, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, dihydropyrimidine dehydrogenase deficiency, hereditary disease, inborn disorder of purine or pyrimidine metabolism, inborn errors of metabolism, intestinal disorder, metabolic disease, neoplasm, rectal disorder	Recruiting	Phase 2	2025-12-10		NCT06245356

Clinical trials